MedTrace Logo

Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

NCT01828762 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2013-12-23

No results posted yet for this study

Summary

Although liver resection, liver transplantation, a-interferon, Transarterial Chemo Embolization (TACE), percutaneous ethanol injection (PEI), Percutaneous microwave coagulation therapy (PMCT), Radiofrequency ablation (RFA) provide options to treat patients with HCC, the high recurrence rate of mid-late stage liver cancer still exists. The safety of autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma (HCC) Patients Following Resection and TACE Therapy will be evaluated.

Conditions

  • Primary Hepatocellular Carcinoma

Interventions

BIOLOGICAL

DC-TC+GM-CSF

Sponsors & Collaborators

  • No.85 Hospital, Changning, Shanghai, China

    collaborator OTHER

  • China Cell Technology Ltd.

    collaborator OTHER

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Chengwei Chen · No.85 Hospital, Changning, Shanghai, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01828762 on ClinicalTrials.gov